US 12,338,439 B2
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
Akin Akinc, Needham, MA (US); Gregory Hinkle, Plymouth, MA (US); Martin A. Maier, Belmont, MA (US); James Butler, Lynnfield, MA (US); and Jingxuan Liu, West Roxbury, MA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Jul. 5, 2023, as Appl. No. 18/218,155.
Application 16/421,745 is a division of application No. 15/800,517, filed on Nov. 1, 2017, abandoned.
Application 18/218,155 is a continuation of application No. 17/121,858, filed on Dec. 15, 2020, abandoned.
Application 17/121,858 is a continuation of application No. 16/421,745, filed on May 24, 2019, granted, now 10,934,544, issued on Mar. 2, 2021.
Application 15/800,517 is a continuation of application No. PCT/US2016/030876, filed on May 5, 2016.
Claims priority of provisional application 62/266,958, filed on Dec. 14, 2015.
Claims priority of provisional application 62/260,887, filed on Nov. 30, 2015.
Claims priority of provisional application 62/157,890, filed on May 6, 2015.
Prior Publication US 2024/0076664 A1, Mar. 7, 2024
Int. Cl. C12N 15/11 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); C07H 21/02 (2006.01); C12N 15/113 (2010.01); C12Q 1/6883 (2018.01)
CPC C12N 15/113 (2013.01) [A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 47/549 (2017.08); C12N 15/1137 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/14 (2013.01); C12N 2310/31 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/344 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Factor XII (Hageman Factor) (F12), or a salt thereof,
wherein the dsRNA agent, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
wherein the sense strand comprises at least 19 contiguous nucleotides from nucleotides 433-460 of the nucleotide sequence of SEQ ID NO:9 and the antisense strand comprises at least 19 contiguous nucleotides from the corresponding nucleotides of the nucleotide sequence of SEQ ID NO:10,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification, and
wherein the sense strand is conjugated to a ligand attached at the 3′-terminus.